Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 8, 2007 - Issue 15
Submit an article Journal homepage
52
Views
4
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Does rosiglitazone increase cardiovascular outcomes?

Sheila A Doggrell Doggrell Biomedical Communications, 14 Quandong Crescent, Nightcliff, NT 0810, Australia mailto:[email protected]
Pages 2665-2669 | Published online: 11 Oct 2007

Bibliography

  • KAHN SE, HAFFNER SM, HEISE MA et al.: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. (2006) 355:2427-2443.
  • NISSEN SE, WOLSKI K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. (2007) 356:2457-2471.
  • HOME PD, POCOCK SJ, BECK-NIELSEN H et al.: Rosiglitazone evaluated for cardiovascular outcomes – an interim analysis. N. Engl. J. Med. (2007) 357:28-38.
  • NESTO RW, BELL D, BONOW RO et al.: Thiazolidinedione use, fluid retention, and congestive heart failure – a consensus statement from the American heart association and American diabetes association. Circulation (2003) 108:2941-2948.
  • CHEN LC, ASHCROFT DM: Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials. J. Clin. Pharmacy Ther. (2006) 31:565-576.
  • MATCHABA P, GITTON X, KRAMMER G et al.: Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials ≥ 1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis. Clin. Ther. (2005) 27:1196-1124.
  • PSATY BM, FURBERG CD: Rosiglitazone and cardiovascular risk. N. Engl. J. Med. (2007) 356:2522-2524.
  • DRAZEN JM, MORRISSEY S, CURFMAN GD: Rosiglitazone – continued uncertainty about safety. N. Engl. J. Med. (2007) 357:63-64.
  • PSATY BM, FURBERG CD: The record on rosiglitazone and the risk of myocardial infarction. N. Engl. J. Med. (2007) 357:67-69.
  • DORMANDY JA, CHARBONNEL B, ECKLAND DJ et al.: Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (PROspective pioglitazone clinical trial in macrovascular events): a randomised trial. Lancet (2005) 366:1279-1289.
  • HOME PD, HONES NP, POCOCK SJ et al.: Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet. Med. (2007) 24:626-634.
  • NATHAN DM: Rosiglitazone and cardiotoxicity – weighing the evidence. N. Engl. J. Med. (2007) 357:64-66.

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.